Atara+Biotherapeutics%2C+Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, announced today the grant of a total of 31,515 restricted stock units of Atara stock to four newly hired employees and stock options to purchase a total of 15,227 shares of Atara common stock from any of these newly hired employees. These awards were approved by the Compensation Committee of Atara’s Board of Directors and granted under Atara Biotherapeutics, Inc.’s 2018 Incentive Plan, with a grant date of July 1, 2022, in as incentive materials for new employees entering employment with Atara, pursuant to Nasdaq listing rule 5635(c)(4).

Restricted share units vest over four years, with 25% vesting on the first quarterly vesting date after the first anniversary of the vesting start date and the remainder vesting in 12 quarterly installments approximately equal to the three years thereafter, provided the employee is continuously employed by Atara from such vesting dates. Stock options vest over four years, with 25% vesting on the first anniversary of the vesting start date for that employee and the remainder vesting in 36 equal monthly installments over the following three years, provided the employee is continuously employed by Atara from such acquisition dates. The stock options have a term of ten years and an exercise price of $8.30 per share, equal to the closing price per share of Atara common stock as reported by Nasdaq on July 1, 2022.

Atara provides this information pursuant to Nasdaq Listing Rule 5635(c)(4).

About Atara Biotherapeutics, Inc.

Atara+Biotherapeutics%2C+Inc. (%40Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematological cancers and autoimmune diseases . With our flagship program in Phase 3 clinical development and currently under review to support registration in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver ready-to-use treatments employment to patients with unmet medical needs. Our platform exploits the unique biology of EBV T cells and has the ability to treat a wide range of EBV-associated diseases, or other serious illnesses through the incorporation of CARs (chimeric antigen receptors) or TCRs (T cell receptors) altered. Atara applies this unique platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel^® (tabelecleucel) in phase 3 development for Epstein-Barr virus-induced post-transplant lymphoproliferative disease (EBV+ PTLD); ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor (CAR-T) T-cell immunotherapies for solid tumors and hematological malignancies. Improving the lives of patients is our mission and we will never stop working to bring transformative therapies to those in need. Atara is headquartered in South San Francisco and our state-of-the-art research, development and manufacturing facilities are based in Thousand Oaks, California. For more information about the company, please visit atarabio.com and follow us on Twitter and LinkedIn.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220701005460/en/